Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

SGHT vs PMI: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PMI Captures Overall Composite Edge (48.4 HOLD vs 34.0 SELL), While SGHT Leads 4–1 on Growth & Valuation Pillars

PMI Overall Winner 6-Pillar Tally: SGHT 4 – 1 PMI (1 Tie) Matrix Metrics: SGHT 4 – 5 PMI

As of Nov 19, 2026, Picard Medical, Inc. (PMI) captures the overall head-to-head institutional edge over Sight Sciences, Inc. (SGHT) on higher Unified Composite conviction (48.4/100 HOLD vs. 34.0/100 SELL) after splitting the core matrix 5–4 (led by Valuation Multiples), while SGHT wins 4–1 across the 6-pillar growth and valuation breakdown. SGHT trades at $10.62 (N/M Forward P/E, -20.2% operating margin) versus PMI at $6.30 (N/M Forward P/E, -248.1% operating margin).

  • Growth vs. Quality Trade-Off: PMI earns the overall head-to-head edge with a stronger Unified Composite Score (48.4/100 HOLD vs. SGHT 34.0/100 SELL) and 54.06β · 134% Vol risk profile, whereas SGHT leads top-line expansion (+25.2% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SGHT vs PMI
SGHT NASDAQ
Sight Sciences, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$10.62
-1.39% 1D
Market Cap $598.6M
TTM Revenue $88M
Forward P/E N/M
Beta / 30D Vol 1.06β · 46% Vol
Unified Composite Score
34.0 / 100 SELL
Tech 50.0 Fund 39.0 Flow 70.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (8.1% over 20 days), RSI 62
RSI-14: 62.2 · SMA20: $10.01 · SMA50: $9.16
PMI NYSE American Head-to-Head Winner
Picard Medical, Inc.
Surgical & Medical Instruments & Apparatus
$6.30
-2.17% 1D
Market Cap $17.1M
TTM Revenue $6.3M
Forward P/E N/M
Beta / 30D Vol 54.06β · 134% Vol
Unified Composite Score
48.4 / 100 HOLD
Tech 39.0 Fund 45.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 42
RSI-14: 42.1 · SMA20: $7.55 · SMA50: $7.62

6-Pillar Scorecard Institutional Category Breakdown (SGHT 4 – 1 PMI)

Columns: Metric · SGHT · PMI
1. Valuation Multiples PMI
Forward P/E N/M N/M
Trailing P/E N/M 2.9x
PEG Ratio N/M N/M
EV / Revenue 6.4x 3.2x
2. Growth & Scale SGHT
Revenue Growth (YoY) +25.2% +38.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $88M $6.3M
Market Cap $598.6M $17.1M
3. Profitability & Quality SGHT
Gross Margin 87.7% 18.6%
Operating Margin -20.2% -248.1%
Net Profit Margin -32.1% 0.0%
Return on Equity (ROE) -50.1% 0.0%
4. Balance Sheet & Cash Flow SGHT
Cash Generation (TTM) -$17M -$17M
Cash Flow Margin -19.1% N/A
Net Cash / Leverage $35M Net Cash $3.2M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SGHT
Options Structure Phase BREAKOUT UNCLASSIFIED
Current IV / %ile 78.7% (8th %ile) N/A (N/A)
Put/Call OI Skew 0.01x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SGHT (4) vs PMI (5)
Institutional Metric SGHT PMI Criterion Row Edge
Market Capitalization
Scale
$598.6M $17.1M Larger Scale SGHT
Trailing P/E Ratio
Valuation
N/M 2.9x Lower Multiple PMI
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+25.2% +38.6% Higher Growth PMI
Operating Margin (TTM)
Profitability
-20.2% -248.1% Higher Margin SGHT
Net Profit Margin
Profitability
-32.1% 0.0% Higher Margin PMI
Return on Equity (ROE)
Capital Efficiency
-50.1% 0.0% Higher ROE PMI
52-Week Range Position
Momentum
88% ($3–$12) 34% ($0–$18) Stronger Trend SGHT
Beta / 30D Volatility
Risk Regime
1.06β · 46% Vol 54.06β · 134% Vol Lower Realized Risk SGHT
Unified Institutional Score
Composite Signal
34.0 / 100 (SELL) 48.4 / 100 (HOLD) Higher Composite PMI
Trailing 12M Revenue (USD)
Operating Scale
$88M $6.3M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
87.7% 18.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.4x EV/Rev N/M PEG · 3.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$17M ($35M Net Cash) -$17M ($3.2M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SGHT +56.65 pp
SGHT: +22.07% · PMI: -34.58%
3M Horizon PMI +67.69 pp
SGHT: +28.57% · PMI: +96.26%
6M Horizon PMI +3323.91 pp
SGHT: +115.42% · PMI: +3439.33%
1Y Horizon PMI +99.29 pp
SGHT: +48.74% · PMI: +148.03%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SGHT Revenue PMI Revenue SGHT Op. Margin PMI Op. Margin Margin Leader
FY2020 $30M N/A -116.5% N/A SGHT
FY2021 $50M N/A -105.2% N/A SGHT
FY2022 $70M N/A -117.7% N/A SGHT
FY2023 $80M N/A -70.7% N/A SGHT
FY2024 $80M $0M -63.3% -312.3% SGHT
FY2025 $80M $0M -48.0% -268.4% SGHT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SGHT BREAKOUT
36d in phase · OBV NEUTRAL
Current IV 78.7%
IV Percentile 8th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact SGHT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PMI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PMI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SGHT Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $598.6M market capitalization and -20.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PMI Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $17.1M market capitalization and -248.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SGHT vs PMI Key Questions & Quantitative Answers

As of Nov 19, 2026, Picard Medical, Inc. (PMI) captures the overall head-to-head institutional edge over Sight Sciences, Inc. (SGHT) on higher Unified Composite conviction (48.4/100 HOLD vs. 34.0/100 SELL) after splitting the core matrix 5–4 (led by Valuation Multiples), while SGHT wins 4–1 across the 6-pillar growth and valuation breakdown. SGHT trades at $10.62 (N/M Forward P/E, -20.2% operating margin) versus PMI at $6.30 (N/M Forward P/E, -248.1% operating margin). Growth vs. Quality Trade-Off: PMI earns the overall head-to-head edge with a stronger Unified Composite Score (48.4/100 HOLD vs. SGHT 34.0/100 SELL) and 54.06β · 134% Vol risk profile, whereas SGHT leads top-line expansion (+25.2% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.

SGHT leads the Growth & Scale pillar: SGHT posts +25.2% YoY revenue growth and +0.0% YoY earnings growth on $88M TTM revenue (87.7% gross margin, -20.2% operating margin), compared with PMI at +38.6% YoY revenue growth and +0.0% YoY earnings growth on $6.3M TTM revenue (18.6% gross margin, -248.1% operating margin). Across the 6-period historical trajectory (FY2020 to FY2025), SGHT cumulative revenue shifted +166.7% while PMI shifted N/A. In operating R&D and SG&A reinvestment, SGHT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PMI.

PMI screens cheaper on headline valuation multiples. SGHT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.4x EV/Revenue (-19.1% FCF margin), whereas PMI trades at N/M Forward P/E, 2.9x Trailing P/E, N/M PEG, and 3.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SGHT (-50.1% ROE) versus PMI (0.0% ROE) capital efficiency.

In options market volatility and institutional positioning, SGHT carries 78.7% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (1.06β · 46% Vol realized risk). By comparison, PMI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (54.06β · 134% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.